Breast Cancer Core Needle Biopsy Market Enabled by Hospital and Diagnostic Laboratory Demand

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Breast Cancer Core Needle Biopsy Market - (By Technology (MRI-based Breast Biopsy, Ultrasound-based Breast Biopsy, Mammography-based (Stereotactic) Breast Biopsy, CT-based Breast Biopsy, Other Image Based Breast Biopsy), By End-use (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Breast Cancer Core Needle Biopsy Market is valued at US$ 697.3 Mn in 2023, and it is expected to reach US$ 1,042.3 Mn by 2031, with a CAGR of 5.34% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2310

Core needle biopsy procedures provide several clinical and economic advantages compared with conventional surgical biopsy techniques, including lower invasiveness, reduced recovery periods, and improved cost efficiency. These benefits, together with the procedure's importance in early disease identification and enhanced patient outcomes, are expected to support sustained growth in the core needle biopsy market. The increasing global focus on early and accurate diagnosis of medical conditions is further contributing to rising demand. During these procedures, tissue or fluid samples are collected and examined microscopically to identify malignant or other abnormal cellular activity.

Ongoing technological progress and innovation in breast biopsy devices are also strengthening market expansion. However, the relatively high cost of breast biopsy procedures and the risk of procedure-related complications may limit broader adoption in certain settings. At the same time, the growing global prevalence of breast cancer is creating significant opportunities for manufacturers to introduce advanced diagnostic solutions.

Key industry participants are actively investing in product portfolio expansion and regulatory approvals to reinforce their competitive positioning. Additionally, educational initiatives such as medical conferences, professional training programs, and public awareness campaigns are improving understanding of cancer detection and prevention, thereby contributing positively to overall market growth.

List of Prominent Players in the Breast Cancer Core Needle Biopsy Market:
• Intact Medical Corporation
• Ethicon Surgical Technologies.
• Galling SRL
• Leica Biosystems Nussle GmbH
• Hologic, Inc
• Argon Medical Devices
• Encapsule Medical Devices LLC.
• Cook Medical Incorporated
• Becton Dickinson and Company
• C.R. Bard, Inc.
• Zenalux Biomedical, Inc.,
• F. Hoffmann-La Roche Ltd.,
• OncoCyte Corporation,
• Laboratory Corporation of America Holdings (LabCorp),
• Scion Medical Technologies,
• Planmed Oy,
• Aurora Imaging Technology Inc.,
• Carestream Health,
• Cardinal Health,
• PerkinElmer
• QIAGEN
• Thermo Fisher Scientific
• Medtronic
• Danaher Corporation
• Others

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers
The increasing prevalence of breast cancer, together with continuous advancements in imaging and biopsy technologies, is a primary factor driving growth in the breast biopsy instruments market. Ongoing technological developments have improved the accuracy, efficiency, and clinical reliability of biopsy procedures, leading to higher adoption across healthcare settings.

At the same time, market participants are responding to rising disease incidence by strengthening promotional and educational initiatives to emphasize the importance of early and accurate diagnosis. Leading companies are focusing on product portfolio expansion and the pursuit of regulatory approvals to enhance their competitive standing. Professional platforms such as medical conferences and clinical forums are also being leveraged to increase awareness and disseminate knowledge related to breast cancer diagnostic solutions.

Challenges
Despite its clinical advantages, core needle biopsy is subject to certain limitations that may restrain market growth. Sampling inaccuracies and inconclusive diagnostic outcomes can occur, particularly in cases influenced by tumor size, density, or anatomical location, potentially resulting in false-negative findings. In addition, patient discomfort and procedural anxiety may reduce acceptance of biopsy procedures, even when clinically indicated. Cost-related factors also present a significant barrier, as the total expense associated with biopsy equipment, specialized clinical expertise, and post-procedure care can restrict access, especially in regions with limited healthcare resources.

Regional Trends
North America is expected to maintain a leading share of the global breast cancer core needle biopsy market, with the United States and Canada serving as key contributors to regional revenue. This dominance is supported by well-developed healthcare infrastructure, advanced diagnostic capabilities, and the growing influence of medical tourism. Meanwhile, the Asia-Pacific region is experiencing rapid market growth, driven by substantial improvements in healthcare infrastructure across emerging economies such as China, India, and South Korea.

Rising awareness of breast cancer screening and diagnosis, along with increased investment in advanced diagnostic technologies-including vacuum-assisted biopsy systems and emerging liquid biopsy approaches-are expanding access to diagnostic services and creating significant opportunities for market expansion in the region.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2310

Recent Developments:
• In Jan 2021, Somatex Medical Technologies GmbH, a market leader in biopsy site markers and localization technologies, was acquired by Hologic, Inc. for an estimated $64 million, the company disclosed this morning. Hologic's approach to offering an all-encompassing collection of groundbreaking solutions spanning the entire spectrum of breast health care was reinforced by the transaction.

Segmentation of Breast Cancer Core Needle Biopsy Market-
By Technology
• MRI-based Breast Biopsy
• Ultrasound-based Breast Biopsy
• Mammography-based (Stereotactic) Breast Biopsy
• CT-based Breast Biopsy
• Other Image Based Breast Biopsy
By End-use
• Hospitals & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes"
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/breast-cancer-core-needle-biopsy-market/2310

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.